High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment

Introduction

Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic in a few months. The rapid spread of this novel coronavirus has been further complicated by a wide spectrum of SARS-CoV-2 disease (COVID-19), spanning asymptomatic or mild disease to multiorgan failure ^1–3. Lacking efficacy-proved treatments, the approach to the management of COVID-19 has been largely empirical, based on indirect data on the antiviral activity of compounds not formally assessed in randomized controlled clinical trials for safety and efficacy ^4,5.

Ritonavir-boosted lopinavir (LPV-r) was initially used as antiviral for SARS-CoV-2 infection based on indirect data. Thus, LPV-r has in vitro inhibitory activity against severe acute respiratory syndrome coronavirus (SARS-CoV) ⁶. In addition, a non-randomized study suggested a positive clinical and virological effect of LPV-r added to ribavirin among patients with SARS-CoV infection ⁷. LPV-r showed in vitro and in an animal model activity against Middle East respiratory syndrome coronavirus (MERS-CoV) ^8,9. Viral clearance was reported for some MERS-CoV cases receiving combinations including LPV-r ¹⁰. Finally, a clinical trial randomizing patients with COVID-19 to standard of care or standard of care plus LPV-r has been reported ¹¹. The median time to clinical improvement was shorter in the group treated with LPV-r in the modified intention-to-treat analysis ¹¹. However, the trial failed to find differences in the primary objective.

One issue with LPV-r is the potential for drug-drug interactions (DDI) affecting a wide variety of commonly used medications ¹². Among those, lipid lowering drugs, antiarrhythmics, cardiovascular drugs, analgesics or anticoagulants are frequently used by aged patients. These older patients are more likely to present with more severe COVID-19 requiring admission and respiratory support, and, due to this, more likely candidates to receive drugs with potential antiviral activity against SARS-CoV-2, as LPV-r. Management of LPV-r by non-infectious diseases doctors, not used to the DDI profile of this drug, along with the need for a fast response and the overwhelming burden of COVID-19 in some areas might have led to a high rate of major DDI between LPV-r and concomitant prescriptions. DDI could have an impact on the tolerability of LPV-r and DDI may even be associated with worse outcomes. However, to our knowledge, there is no data on the frequency and impact of DDI between LPV-r to treat patients with COVID-19 and commonly used drugs in clinical practice. Because of these, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and concomitant medications.

Results

Discussion

In the present study, we found a high overall frequency of DDI between LPV-r for treating COVID-19 and concomitant medications. Moreover, nearly one third of the patients were treated with commonly used medications with major DDI with LPV-r. Patients in whom major DDI were observed showed a worse clinical outcome, but this association was explained by the older age and comorbidities of these patients. Finally, patients managed by the Infectious Diseases Unit had lower risk of major DDI.

Coadministration of LPV-r with drugs that are major substrates of and highly dependent on CYP3A for clearance is associated with increased plasma concentrations of such drugs or their metabolites. In our study, many commonly used medications with that metabolic interaction with LPV-r were prescribed to patients with COVID-19. Antiarrhythmics, symvastatin or budesonide were found to be administered to the study patients. Elevated plasma concentrations of some of those medications are associated with life-threatening reactions. In this regard, we found a significantly higher frequency of deaths among patients who were treated with medications with major DDI with LPV-r. However, after adjustment in a multivariate model, drugs with major DDI with LPV-r were not independently associated with the risk of death. Instead, the main predictor of death was the Charlson index. Therefore, the patient profile, i.e. older individuals with concomitant diseases needing drugs posing contraindications with LPV-r, accounted for the association between deaths and major interactions with LPV-r.

Patients with COVID-19 treated with LPV-r in the present study were severely ill. The majority needed admission and had high Charlson index scores. More importantly, the overall death rate was 21%, i.e. greater than the mortality reported in hospitalized patients in China ^1,2. The older age of patients and their elevated Charlson index could explain the higher death rate in our study.

Discontinuations of LPV-r due to adverse events among HIV-infected patients were lower than 10% after two years of antiretroviral treatment ¹⁴. In a randomized clinical trial of LPV-r for COVID-19 in China, patients stopped early a course of 14 days of LPV-r even more frequently ¹¹. Nearly 14% of LPV-r recipients were unable to complete treatment due to adverse events in that trial. In our study, one fourth of the patients discontinued LPV-r because of severe adverse events. The aged and fragile population receiving LPV-r in our study could be more prone to develop LPV-r-related side effects. In fact, our study population was older and accumulated more coexisting conditions than the patients recruited in the Chinese trial of LPV-r for COVID-19 ¹¹. The elevated frequency of LPV-r discontinuations in fragile patients with severe COVID-19 questions the clinical applicability of LPV-r as antiviral in such patients.

We found that major DDI between comedications and LPV-r were more frequent among patients managed by non-Infectious Diseases Units compared with the Infectious Diseases Unit. After adjustment by the Charlson index, an independent association between major DDI with LPV-r and the treating unit was confirmed. A few factors could explain this finding. First, the overwhelming COVID-19 crisis in our center led to admitting patients with COVID-19 in wards other than the Infectious Diseases ward. In this situation, treatment stewardship by Infectious Diseases doctors was not feasible. Second, management by Infectious Diseases specialists has demonstrated to improve the outcome of patients with other infections ^15,16. However, even Infectious Diseases physicians, more aware of the DDI of ritonavir-boosted HIV protease inhibitors than other specialists, exposed patients to major DDI with LPV-r. The complexity of patients, staff shortage due to quarantines of doctors falling ill or exposed to unprotected close contacts, and the many difficulties imposed by a health crisis might partly explain those prescription mistakes.

The present study may have some limitations. First, due to LPV-r supply shortage, this antiviral drug was restricted mostly to more severe patients, those requiring hospitalization. This population represents an extreme of the pandemic, with more complications needing medical intervention and worse outcomes. LPV-r given to younger and less fragile patients might have been more tolerable, with less DDI and discontinuations. Second, post-discharge deaths at home or nursing facilities were not evaluated, only deaths during admissions or at the emergency room were evaluable for the present study. Death rates could have been even higher than those reported herein with a follow-up after discharge, as suggested by another study ¹⁷. Third, the main source of data was the electronic clinical records and the Pharmacy electronic prescriptions. This might have precluded detailed medical record review and it could have led to data loss. However, currently in the Andalusian Health System, health and medical records of every patient are collected in a common electronic database by all caring physicians and nurses. Medications are also prescribed using electronic prescriptions both for outpatients and inpatients. In this regard, individual patient electronic medical records were manually evaluated. These are strengths of the present study.

In conclusion, LPV-r for hospitalized patients with COVID-19 frequently interacts with concomitant medications. Major DDI contraindicating the coadministration of LPV-r and common medications were alarmingly overlooked in the setting of the COVID-19 health care crisis. Safer antiviral treatments for COVID-19, with a better interaction profile, are clearly warranted.

Patients and methods

This was a cross-sectional study. All individuals diagnosed of SARS-CoV-2 infection from March 1^st to April 30^th, 2020 attended at a single center in Seville, Southern Spain, were evaluated to identify those treated with LPV-r. All patients with COVID-19, confirmed by SARS-CoV-2 PCR or serology, who were prescribed LPV-r as a part of their treatment for SARS-CoV-2 infection were included. The electronic clinical records and Pharmacy electronic prescriptions of all patients were examined to select those who received at least one dose of LPV-r. Concomitant medications were collected from the electronic prescriptions. The electronic clinical records were used to identify comorbid conditions to calculate the Charlson index for each patient ¹³. The vital status of patients was established querying electronic clinical records and it was last updated in May 22^nd, 2020.

DDI were evaluated using the COVID-19 Drug Interactions site (https://www.covid19-druginteractions.org/) by the Liverpool Drug Interaction Group. The frequency and grade of DDI was assessed. DDI were graded, according to the Liverpool Drug Interaction Group, as potential and major. Potential DDI does not preclude co-administration, since they are usually manageable, but they indicate the need to balance risks and benefits for an individual patient. Major DDI correspond to the “do not co-administer” classification of the Liverpool Drug Interaction Group. The death rate by the severity of DDI was assessed. In addition, side effects leading to discontinuation of LPV-r were examined.

Data availability

All data generated or analyzed during this study are included in this article.

Author contributions statement

Study concept and design: JM, JAP, LMR, RMV

Acquisition of data: AP, FLD, AC, ECM, AGS, AGP, MFF, MT

Analysis and interpretation of data: JM, JAP, LMR

Drafting of the manuscript: JM, JAP, LMR, RMV

Critical revision of the manuscript: All authors.

Final approval: All authors

Competing interests

The authors declare that they have no competing interests.